非戈替尼治疗中重度活动性类风湿关节炎患者中位1.6年治疗的综合安全性分析
整合七项试验共3691例接受非戈替尼治疗的中重度活动性类风湿关节炎患者数据,中位暴露1.6年、最长5.6年。安慰剂对照期至第12周,非戈替尼200mg与100mg的治疗中出现的不良事件发生率与安慰剂相当;长期按治疗分析数据集中,200mg组感染发生率低于100mg组。
要点
- 3691例患者接受非戈替尼治疗,累积暴露6080.7患者年,中位1.6年、最长5.6年。
- 安慰剂对照期至第12周,非戈替尼与安慰剂的不良事件发生率相当,包括≥3级事件。
- 长期按治疗分析中,200mg组严重感染和带状疱疹发生率低于100mg组。
核心结论
- 在中位1.6年、最长5.6年的暴露期间,非戈替尼200mg与100mg的安全性和耐受性相似。
- 长期按治疗分析数据集中,非戈替尼200mg组的感染发生率低于100mg组。
研究设计与样本
- 整合七项试验(NCT01668641、NCT01894516、NCT02889796、NCT02873936、NCT02886728、NCT02065700、NCT03025308)的数据。
- 分析安慰剂对照期(至第12周)和长期按治疗分析数据集(接受至少1剂非戈替尼200mg或100mg每日治疗患者的全部可用数据)。
- 计算非戈替尼暴露每100患者年的暴露调整发生率(EAIRs/100PYE)用于治疗中出现的不良事件(TEAEs)。
- 共3691例患者接受非戈替尼治疗,累积暴露6080.7患者年,中位1.6年,最长5.6年。
主要发现
- 安慰剂对照期,非戈替尼与安慰剂的TEAEs发生率相当,包括≥3级TEAEs。
- 长期按治疗分析中,≥3级TEAEs的EAIRs在非戈替尼200mg组为6.4/100PYE,在100mg组为7.6/100PYE。
- 死亡EAIRs在非戈替尼200mg、100mg和安慰剂组均为0.6/100PYE;长期EAIRs在200mg组为0.5/100PYE,在100mg组为0.3/100PYE。
- 严重感染EAIRs在非戈替尼200mg、100mg和安慰剂组分别为3.9、3.3和2.4/100PYE;长期EAIRs在200mg组为1.6/100PYE,在100mg组为3.1/100PYE。
- 带状疱疹EAIRs在非戈替尼200mg、100mg和安慰剂组分别为0.6、1.1和1.1/100PYE;长期EAIRs在200mg组为1.8/100PYE,在100mg组为1.1/100PYE。
关键数值与推荐
- 主要不良心血管事件EAIRs在非戈替尼200mg、100mg和安慰剂组分别为0、1.7和1.1/100PYE;长期EAIRs在200mg组为0.4/100PYE,在100mg组为0.6/100PYE。
- 安慰剂对照期无静脉血栓栓塞发生;长期EAIRs在非戈替尼200mg组为0.2/100PYE,在100mg组为0/100PYE。
- 长期按治疗分析中,非戈替尼200mg组严重感染EAIR为1.6/100PYE,低于100mg组的3.1/100PYE。
- 长期按治疗分析中,非戈替尼200mg组带状疱疹EAIR为1.8/100PYE,高于100mg组的1.1/100PYE。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterise safety of the Janus kinase-1 preferential inhibitor filgotinib in patients with moderately to severely active rheumatoid arthritis. METHODS: Data were integrated from seven trials (NCT01668641, NCT01894516, NCT02889796, NCT02873936, NCT02886728, NCT02065700, NCT03025308). Results are from placebo (PBO)-controlled (through week (W)12) and long-term, as-treated (all available data for patients receiving ≥1 dose filgotinib 200 (FIL200) or 100 mg (FIL100) daily) datasets. We calculated exposure-adjusted incidence rates (EAIRs)/100 patient-years filgotinib exposure (100PYE) for treatment-emergent adverse events (TEAEs). RESULTS: 3691 patients received filgotinib for 6080.7 PYE (median 1.6, maximum 5.6 years). During the PBO-controlled period, TEAEs, including those of grade ≥3, occurred at comparable rates with filgotinib or PBO; long-term EAIRs of TEAEs grade ≥3 were 6.4 and 7.6/100PYE for FIL200 and FIL100. EAIRs for deaths were 0.6/100PYE for FIL200, FIL100 and PBO; long-term EAIRs were 0.5 and 0.3/100PYE for FIL200 and FIL100. EAIRs for serious infection were 3.9, 3.3 and 2.4/100PYE for FIL200, FIL100 and PBO; long-term EAIRs were 1.6 and 3.1/100PYE for FIL200 and FIL100. EAIRs for herpes zoster were 0.6, 1.1, and 1.1/100PYE for FIL200, FIL100 and PBO; long-term EAIRs were 1.8 and 1.1/100PYE for FIL200 and FIL100. EAIRs for major adverse cardiovascular events were 0, 1.7 and 1.1/100PYE for FIL200, FIL100 and PBO; long-term EAIRs were 0.4 and 0.6/100PYE for FIL200 and FIL100. No venous thromboembolism occurred during the PBO-controlled period; long-term EAIRs were 0.2 and 0/100PYE for FIL200 and FIL100. CONCLUSIONS: Over a median of 1.6 and maximum of 5.6 years of exposure, safety/tolerability of FIL200 and FIL100 were similar, with a lower incidence of infections with FIL200 among the long-term, as-treated dataset.
引用
- Winthrop KL, Tanaka Y, Takeuchi T, et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis. 2021. PMID: 34740884. doi:10.1136/annrheumdis-2021-221051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。